Mid Atlantic Bio Angels

About Mid Atlantic Bio Angels

This author has not yet filled in any details.
So far Mid Atlantic Bio Angels has created 46 blog entries.

MABA’s 2023 ACA Innovation Nominee TSSC Honored with Prestigious Luis Villalobos Award

NEW YORK CITY, NEW YORK, UNITED STATES OF AMERICA, May 31, 2023/EINPresswire.com/ — Mid Atlantic Bio Angels (MABA), a NY-based life angel investor group, is pleased to announce that its nominee The Shape Sensing Company (TSCC) has received the prestigious 2023 Luis Villalobos Award in recognition of industry innovation by disruptive companies operating at the forefront of their respective fields, who have been recently financed by members of the Angel Capital Association (ACA).

The award is in honor of Luis Villalobos, founder of [ Read more… ]

2023-06-01T17:25:30+00:00May 31st, 2023|

MedCity INVEST Ask the Investor Spotlight: Yaniv Sneor of Mid Atlantic Bio Angels

Yaniv Sneor, the co-founder of Mid Atlantic Bio Angels and part of the Ask the Investor sessions at MedCity INVEST this week, explained what his firm looks for in life science startups.

Healthcare and life science startups have the opportunity to network and engage in salon-style discussions with investors as part of the Ask the Investor sessions. They will be held during the breakfast segments of INVEST on [ Read more… ]

2023-06-01T11:57:19+00:00May 23rd, 2023|

MABA Portfolio Company Cerus Endovascular Acquired by Stryker

NEW YORK CITY, NY, USA, May 9, 2023/EINPresswire.com/ — Mid Atlantic Bio Angels (MABA), a NY-based life science angel investor group, announced today that one of its portfolio companies, Cerus Endovascular Ltd, was acquired in a large transaction by Stryker. Cerus Endovascular Ltd, a UK-based, privately held, commercial stage medical device company focused on the design and development of neurointerventional devices for the treatment of intracranial aneurysms, will join the portfolio of Stryker, one of the world’s leading medical technology companies.

MABA’s investment in Cerus Endovascular (Cerus) underscores its commitment to supporting companies that it believes will greatly elevate the standard [ Read more… ]

2023-05-25T09:12:36+00:00May 9th, 2023|



Hilltop Bio makes advanced regenerative therapies that have been tailored for practical applications in veterinary practices. They stimulate cell-to-cell communication that is essential for healing by delivering an intracellular, cell-signaling cascade of cytokines, growth factors, and exosomes that accelerates tissue repair and establishes normal tissue functionality.


Hilltop Bio Investor Update Q1 2023

Mid Atlantic Bio Angels Invests in Veterinary Biotech Company Hilltop Bio



2023-05-11T12:33:04+00:00April 8th, 2023|

Mid Atlantic Bio Angels Invests in Veterinary Biotech Company Hilltop Bio

Mid Atlantic Bio Angels, a NY-based angel investor group, is investing in Hilltop Bio, a veterinary biotech company. The MABA investment includes individual investors; MABA’s internal investment Pool III; and the MABA Sidecar Fund II, a co-investment fund for non-MABA members

Hilltop Bio’s products, in development and commercialized, are regenerative therapies that help reduce pain, inflammation, healing time, scar tissue, and reinjury rates. Equine and small animal veterinarians benefit due to the ease of everyday use, storage, and consistent product profile. Veterinarians can also reduce the number of visits a client makes [ Read more… ]

2023-04-08T20:05:54+00:00March 31st, 2023|


-By Anthony Gellert

There’s never been a better time to invest in early-staged startups. Full stop.

Yes, there was a banking crisis in Silicon Valley. Yes, we are still brushing off the effects of the pandemic. Yes, these are very risky assets. But most important, all the asset classes that rely on low interest rates and a bull market are in real trouble. Interest rates are now too low to fully guard against inflation. And too high to make equities the obvious first choice. This especially includes later-staged VC, which relies on frothy IPO markets in which to sell their portfolio companies.

Early-staged [

2023-03-30T13:58:53+00:00March 30th, 2023|


Posted: January 30, 2023

Happy New Year, and welcome aboard, for those investors who recently joined Sidecar Fund II as investors.

Over the last year, MABA has made several new investments as well as several follow-on investments in existing portfolio companies.  A few of these qualified for co-investment by the Fund.

Due to the unique structure of Fund II, which is an open-ended Fund, different investors will end up with different baskets of portfolio companies, depending on the time they joined the Fund.

To make sure that you are able to see updates from the companies in your specific portfolio, we’ve designed and [ Read more… ]

2023-04-08T20:08:36+00:00January 30th, 2023|

Is Angel Capital or Venture Capital Right for Your Company?

MABA is regularly approached by companies seeking funds for their life sciences startups (therapeutics, devices, diagnostics and digital health). One of the first things we discuss is their total funding needs to reach an exit, and the difference between angel and venture capital (VC). Understanding the difference can help you set the best strategy for your company. Once you have reached the stage where it is time to raise funds, some companies are better suited for, or would prefer angel funding, while others are more appropriate for venture capital. 

There are many differences between angel investors and VCs, including the source [ Read more… ]

2022-12-07T13:56:04+00:00December 7th, 2022|
Go to Top